Biopharma SHAKTI commits Rs. 10,000 crore to scale biologics manufacturing, translational research, and supply chains over five years, a strategic bet on biosimilars, advanced therapies, and domestic capacity. The fund aims to foster industry-academia incubators, incentives for advanced production, and a stronger export orientation. If executed, the scheme could reduce import dependence, lower therapy costs, and attract global investment into India’s next-generation drug industry. This measure requires clear timelines and state-level coordination.
Trending
- Key convicted Palestine Action member on the run
- Mental wellbeing improves across the mortgage industry, but risks remain: MIMHC
- The Power of Visualization & 6 Steps to Help You Improve Yours
- Bonds and Biology: How Social Media Engages Reward Systems
- Human Resources: Making Return to Work Feel Like Return to Home
- Feather Preserved in Dinosaur Dung Could Explain Why Birds Survived Mass Extinction
- Following Timor-Leste’s Triumph, All of Southeast Asia Has Eliminated Trachoma
- Thara Brigitte Mills Simmonds wins the forty-under-40 education award
Monday, September 14
